ArticleBMC veterinary research2026
A monoclonal antibody-based, time-resolved fluorescence microsphere immunochromatographic testing strip for rapid and sensitive detection of H7 avian influenza viruses.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAvian influenza viruses (AIVs), particularly the H7N9 subtype, pose a persistent threat to global health security, having caused 1,687 human infections and 615 deaths to date. The significant socioeconomic impact and pandemic potential of H7N9 underscore the urgent need for rapid, reliable diagnostic tools to facilitate early intervention and control measures.
methodsThis study conducted on 2025 developed and optimized a time-resolved fluorescence microsphere immunochromatographic strip (TRFICS) assay for the rapid detection of H7 AIVs. The assay was constructed using two specific monoclonal antibodies, 2H9 and 1H9. Comprehensive evaluations were conducted to assess the assay’s sensitivity, specificity, reproducibility, and stability. Furthermore, clinical utility was validated by comparing TRFICS results with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) using field samples (collected from 2013 to 2025).
resultsThe optimized TRFICS assay achieved limits of detection (LOD) of 2–5 hemagglutination units (HAU) for H7N9 in allantoic fluid and 0.01 ng/mL for purified H7N9 hemagglutinin protein within 15 min. The assay demonstrated 100% concordance with RT-qPCR results in field sample testing. High specificity was observed with no cross-reactivity against other prevalent pathogens. Additionally, the assay exhibited excellent repeatability (relative standard deviation < 8%) and maintained stable performance under various storage conditions.
conclusionThe developed TRFICS assay represents a robust, sensitive, and rapid platform for the on-site identification of H7 AIVs. Its superior performance characteristics make it a valuable tool for effective surveillance and timely response to potential H7 AIV pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.